Complete Up To Date Information about Bizolin -200.
NADA Number: 047-712 | |
| Proprietary Name |
Bizolin®-200 Bizolin®-100 |
|---|---|
| Sponsor |
Boehringer Ingelheim Vetmedica, Inc. |
| Sponsor Address |
2621 North Belt Highway St.Joseph, MO 64502 USA |
| Ingredients |
Phenylbutazone |
| Species |
Horse, not for meat production Dog, no use class stated or implied |
| Routes of Administration |
Per Os |
| Dose Form |
Tablet |
| Drug Form |
Tablet |
| Dispensing Status |
RX |
|
Dosage Amount, Indications & Limitations |
520.1720a Phenylbutazone tablets and boluses. Specifications: Each tablet contains 100 or 200 milligrams, or 1 gram of phenylbutazone. Conditions of use: Dogs Amount: 20 milligrams per pound of body weight daily. Administer in three divided doses daily. Do not exceed a total daily dose of 800 milligrams regardless of body weight. Administer at a relatively high dosage level for the first 48 hours and then reduce gradually to a maintenance dosage level with the lowest dosage maintained at a level capable of producing the desired clinical response. Indications: The drug is used for the relief of inflammatory conditions associated with a musculoskeletal system. Limitations: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Horses Amount: One to two grams per 500 pounds weight daily. Do not exceed a daily dosage of 4 grams per day. Administer at a relatively high dosage level for the first 48 hours and then reduce gradually to a maintenance dosage level the lowest dosage maintained at the level capable of producing the desired clinical response. Indications: This drug is used for the relief of inflammatory conditions associated with the musculoskeletal system. Limitations: Not for use in animals intended for food purposes. Federal law restricts this drug to use by or on the order of a licensed veterinarian. NAS/NRC status: These conditions are NAS/NRC reviewed and deemed effective. Applications for these uses need not include effectiveness data as specified by 514.111 of this chapter, but may require bioequivalency and safety information. |